<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
      <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosone</journal-id>
      <journal-title-group>
        <journal-title>PLoS ONE</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1932-6203</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22558227</article-id>
      <article-id pub-id-type="pmc">3340413</article-id>
      <article-id pub-id-type="publisher-id">PONE-D-12-03075</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pone.0035807</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Biochemistry</subject>
            <subj-group>
              <subject>Proteins</subject>
              <subj-group>
                <subject>Protein Chemistry</subject>
                <subject>Protein Structure</subject>
              </subj-group>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Biophysics</subject>
            <subj-group>
              <subject>Protein Chemistry</subject>
              <subject>Protein Folding</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Neurology</subject>
            <subj-group>
              <subject>Dementia</subject>
              <subj-group>
                <subject>Alzheimer Disease</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Physics</subject>
          <subj-group>
            <subject>Biophysics</subject>
            <subj-group>
              <subject>Protein Folding</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Amyloid-Beta (A&#x3B2;) D7H Mutation Increases Oligomeric A&#x3B2;42 and Alters Properties of A&#x3B2;-Zinc/Copper Assemblies</article-title>
        <alt-title alt-title-type="running-head">A&#x3B2;D7H Mutation Alters Ion-Induced Aggregates</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Wei-Ting</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hong</surname>
            <given-names>Chen-Jee</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lin</surname>
            <given-names>Ya-Tzu</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chang</surname>
            <given-names>Wen-Han</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>He-Ting</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liao</surname>
            <given-names>Jhih-Ying</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chang</surname>
            <given-names>Yu-Jen</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hsieh</surname>
            <given-names>Yi-Fang</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>Chih-Ya</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Hsiu-Chih</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
          <xref ref-type="aff" rid="aff9">
            <sup>9</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Yun-Ru</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>Irene H.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <addr-line>Institute of Brain Science, National Yang Ming University, Taipei, Taiwan</addr-line>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <addr-line>Division of Psychiatry, National Yang Ming University, Taipei, Taiwan</addr-line>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <addr-line>Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan</addr-line>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <addr-line>Division of Neurology, National Yang Ming University, Taipei, Taiwan</addr-line>
      </aff>
      <aff id="aff5">
        <label>5</label>
        <addr-line>Brain Research Center, National Yang Ming University, Taipei, Taiwan</addr-line>
      </aff>
      <aff id="aff6">
        <label>6</label>
        <addr-line>Genomics Research Center, Academia Sinica, Taipei, Taiwan</addr-line>
      </aff>
      <aff id="aff7">
        <label>7</label>
        <addr-line>Taiwan International Graduate Program in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei, Taiwan</addr-line>
      </aff>
      <aff id="aff8">
        <label>8</label>
        <addr-line>Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan</addr-line>
      </aff>
      <aff id="aff9">
        <label>9</label>
        <addr-line>Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Bush</surname>
            <given-names>Ashley I.</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">Mental Health Research Institute of Victoria, Australia</aff>
      <author-notes>
        <corresp id="cor1">* E-mail: <email>hjcheng@ym.edu.tw</email> (IHC); <email>yrchen@gate.sinica.edu.tw</email> (YRC)</corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: WTC IHC YRC. Performed the experiments: WTC WHC YTL HTH JYL CYC YJC YFH. Analyzed the data: WTC IHC YRC. Contributed reagents/materials/analysis tools: CJH HCL. Wrote the paper: WTC CJH IHC.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>4</month>
        <year>2012</year>
      </pub-date>
      <volume>7</volume>
      <issue>4</issue>
      <elocation-id>e35807</elocation-id>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>1</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>3</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement>
        <copyright-year>2012</copyright-year>
      </permissions>
      <abstract>
        <p>Amyloid precursor protein (APP) mutations associated with familial Alzheimer's disease (AD) usually lead to increases in amyloid &#x3B2;-protein (A&#x3B2;) levels or aggregation. Here, we identified a novel APP mutation, located within the A&#x3B2; sequence (A&#x3B2;<sub>D7H</sub>), in a Taiwanese family with early onset AD and explored the pathogenicity of this mutation. Cellular and biochemical analysis reveal that this mutation increased A&#x3B2; production, A&#x3B2;42/40 ratio and prolonged A&#x3B2;42 oligomer state with higher neurotoxicity. Because the D7H mutant A&#x3B2; has an additional metal ion-coordinating residue, histidine, we speculate that this mutation may promote susceptibility of A&#x3B2; to ion. When co-incubated with Zn<sup>2+</sup> or Cu<sup>2+</sup>, A&#x3B2;<sub>D7H</sub> aggregated into low molecular weight oligomers. Together, the D7H mutation could contribute to AD pathology through a &#x201C;double punch&#x201D; effect on elevating both A&#x3B2; production and oligomerization. Although the pathogenic nature of this mutation needs further confirmation, our findings suggest that the A&#x3B2; N-terminal region potentially modulates APP processing and A&#x3B2; aggregation, and further provides a genetic indication of the importance of Zn<sup>2+</sup> and Cu<sup>2+</sup> in the etiology of AD.</p>
      </abstract>
      <counts>
        <page-count count="12"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Alzheimer's disease (AD) is characterized neuropathologically by progressive brain deposition of the amyloid &#x3B2; peptide (A&#x3B2;), which is generated by proteolytic cleavage of amyloid precursor protein (APP) by &#x3B2;- and &#x3B3;-secretases (<xref ref-type="fig" rid="pone-0035807-g001">Fig. 1A</xref>). The two most common A&#x3B2; variants have 40 (A&#x3B2;40) or 42 (A&#x3B2;42) amino acids. The abnormal aggregation and accumulation of neurotoxic A&#x3B2; have been proposed as the primary driving force for AD in the amyloid hypothesis <xref ref-type="bibr" rid="pone.0035807-Hardy1">[1]</xref>.</p>
      <fig id="pone-0035807-g001" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0035807.g001</object-id>
        <label>Figure 1</label>
        <caption>
          <title>A novel mutation leads to an aspartate to histidine substitution at the N-terminus of A&#x3B2;.</title>
          <p>(A) The upper part of the diagram presents the A&#x3B2;42 sequence with the location of the D7H mutation (red). As shown in the lower part of the diagram, processing of APP occurs via two pathways. Nonamyloidogenic processing of APP by &#xE1;-secretase produces the C83 and sAPP&#x3B1; fragments; amyloidogenic processing of APP by &#xE2;-secretase produces the C99 and sAPP&#x3B2; fragments. A&#x3B2; is generated through subsequent cleavage of C99 by &#x3B3;-secretase. (B) SPECT images of the index patient indicate hypoperfusion in the bilateral parietal cortices and the left temporal cortex. (C) Direct sequencing of APP exon 16 PCR products derived from the patient and from healthy controls revealed a GAC-to-CAC nucleotide substitution in A&#x3B2; region of the patient's APP gene (in 678<sup>th</sup> amino acid using APP770 numbering or in 7<sup>th</sup> amino acid using A&#x3B2; numbering).</p>
        </caption>
        <graphic xlink:href="pone.0035807.g001"/>
      </fig>
      <p>A&#x3B2; aggregation undergoes multiple pathways with a variety of intermediates/oligomers formation. The current notion is that low molecular weight (LMW) assemblies such as soluble oligomers and protofibrils, but not fibril, are the primary toxic structures of A&#x3B2; <xref ref-type="bibr" rid="pone.0035807-Lesne1">[2]</xref>, <xref ref-type="bibr" rid="pone.0035807-Shankar1">[3]</xref>. However, due to the highly dynamic nature of A&#x3B2; assemblies and the technical limitation, biochemical features of toxic A&#x3B2; aggregates remain unclear <xref ref-type="bibr" rid="pone.0035807-Glabe1">[4]</xref>.</p>
      <p>Mutations in the APP gene lead to the early onset familial AD. Most APP mutations are concentrated either around or within the A&#x3B2; domain. APP mutations at the secretase cleavage sites accelerate the production of A&#x3B2;, particularly the highly pathogenic A&#x3B2;42 <xref ref-type="bibr" rid="pone.0035807-Felsenstein1">[5]</xref>, <xref ref-type="bibr" rid="pone.0035807-Maruyama1">[6]</xref>, <xref ref-type="bibr" rid="pone.0035807-Suzuki1">[7]</xref>, <xref ref-type="bibr" rid="pone.0035807-Zhou1">[8]</xref>, <xref ref-type="bibr" rid="pone.0035807-Grabowski1">[9]</xref>. Mutations clustered within the 21<sup>st</sup>&#x2013;23<sup>rd</sup> residues of A&#x3B2; involve enhancing A&#x3B2; aggregation, delaying A&#x3B2; elimination or increasing A&#x3B2; production <xref ref-type="bibr" rid="pone.0035807-Grabowski1">[9]</xref>, <xref ref-type="bibr" rid="pone.0035807-Haan1">[10]</xref>, <xref ref-type="bibr" rid="pone.0035807-Hendriks1">[11]</xref>, <xref ref-type="bibr" rid="pone.0035807-Nilsberth1">[12]</xref>, <xref ref-type="bibr" rid="pone.0035807-Cheng1">[13]</xref>. Mutations located at A&#x3B2; N-terminus, including the English (H6R) and Tottori (D7N) mutations, have been shown to enhance fibril formation without altering A&#x3B2; production <xref ref-type="bibr" rid="pone.0035807-Hori1">[14]</xref>. Several potential therapeutic strategies aimed at reducing A&#x3B2; production, inhibiting A&#x3B2; aggregation, and speeding A&#x3B2; removal are being developed <xref ref-type="bibr" rid="pone.0035807-Golde1">[15]</xref>.</p>
      <p>Metal ions, especially Zn<sup>2+</sup> and Cu<sup>2+</sup>, have been shown to abnormally accumulate in the amyloid plaques of patients with AD <xref ref-type="bibr" rid="pone.0035807-Lovell1">[16]</xref>. The interplay of metal-A&#x3B2; interaction has been strengthened recently <xref ref-type="bibr" rid="pone.0035807-Tugu1">[17]</xref>. Metal ions with redox activity, such as Cu<sup>2+</sup> and Fe<sup>3+</sup>, induce free radicals through the formation of A&#x3B2;-ion complex <xref ref-type="bibr" rid="pone.0035807-Smith1">[18]</xref>. Zn<sup>2+</sup> and Cu<sup>2+</sup> are known to bind the histidine residues at A&#x3B2; N-terminus <xref ref-type="bibr" rid="pone.0035807-Minicozzi1">[19]</xref>, <xref ref-type="bibr" rid="pone.0035807-Nair1">[20]</xref>. The metal chelation therapy is now a potential treatment for AD and undergoing clinical phase IIb trial <xref ref-type="bibr" rid="pone.0035807-Duce1">[21]</xref>, <xref ref-type="bibr" rid="pone.0035807-Faux1">[22]</xref>. However, disruption of ion homeostasis in the central nervous system by the use of metal chelator may further deplete the essential metal ions and cause negative impact on the disease progress <xref ref-type="bibr" rid="pone.0035807-Hegde1">[23]</xref>. Therefore, to specify the features of the A&#x3B2;-ion complex could help to improve the pharmacological design.</p>
      <p>Here, we report a novel intra-A&#x3B2; mutation (D7H) in a Taiwanese family with early onset AD. Because the number of patients is limited, we explored the pathogenicity of this mutation with experimental approaches. we propose this mutation is probable pathogenic because the D7H mutation resulted in increased levels total A&#x3B2;, in a higher A&#x3B2;42/40 ratio and in the formation of A&#x3B2;40 fibrils while prolonged A&#x3B2;42 oligomers state with higher toxicity. Furthermore, we speculated that the appearance of one more histidine at the 7<sup>th</sup> residue of mutant A&#x3B2; may enhance susceptibility to the effect of Zn<sup>2+</sup> or Cu<sup>2+</sup>. Our study reveals that this mutation increased the binding of Zn<sup>2+</sup> and Cu<sup>2+</sup> and promoted the formation of ion-induced A&#x3B2; oligomers with altered morphology. Together, our clinical and experimental results suggest a pathogenic role of the D7H mutation in familial AD. We also provide a &#x201C;genetic hint&#x201D; for the studies in the metal as etiology in AD.</p>
    </sec>
    <sec id="s2">
      <title>Results</title>
      <sec id="s2a">
        <title>Clinical description and genetic analysis</title>
        <p>We identified a 53 year-old female AD patient who had multiple family members affected with memory impairment before age 65 (<xref ref-type="supplementary-material" rid="pone.0035807.s001">Fig. S1A</xref>). The index patient had been showing progressive memory impairment, slurred speech, persecutory delusions, self-talking and inability to dress herself since age 51. She was restless and asked the same questions repeatedly during the clinical examinations. The scores of the mini mental status examination and the Wechsler Adult Intelligence Scale were 13 and 62, respectively. The computed tomography (CT) scans revealed diffuse prominent cerebral fissures, cisterns and sulci. The Tc-99 m HMPAO single photon emission computed tomography (SPECT) scans showed hypoperfusion in the bilateral parietal and left temporal cortices (<xref ref-type="fig" rid="pone-0035807-g001">Fig. 1B</xref>). Diffuse background slow waves (6&#x2013;7 Hz) were noted by electroencephalography. The results of blood biochemistry tests for liver function, renal function, thyroid function, anemia and syphilis were all within normal limits (<xref ref-type="supplementary-material" rid="pone.0035807.s001">Fig. S1B</xref>). Diagnosis of probable AD was made according to the NINCDS&#x2013;ADRDA criteria. Mutation analysis was done by directly sequencing PCR-amplified coding exons of <italic>PSEN1</italic>, <italic>PSEN2</italic> and <italic>APP</italic>. Sequencing revealed a G&#x2192;C nucleotide substitution in the <italic>APP</italic> gene, resulting in an aspartate to histidine mutation at 7<sup>th</sup> position of A&#x3B2; (D678H using APP770 numbering or D7H using A&#x3B2; numbering, <xref ref-type="fig" rid="pone-0035807-g001">Fig. 1C</xref>). This mutation has never been reported and was not found in 100 unrelated healthy controls and 100 Chinese AD patients.</p>
        <p>Due to the limited number of patients, we tried to determine the pathogenicity of this mutation by functional analysis. Both cells expressing human APP and synthetic A&#x3B2; peptides were used to explore the levels of A&#x3B2; production, A&#x3B2;42/40 ratio and A&#x3B2; aggregation process.</p>
      </sec>
      <sec id="s2b">
        <title>The D7H mutation on APP enhances amyloidogenic cleavage and increases the A&#x3B2;42/40 ratio</title>
        <p>In the non-amyloidogenic pathway, cleavage of APP within the A&#xE2; region by &#x3B1;-secretase generates a secreted N-terminal fragment &#x3B1; (sAPP&#x3B1;) and an 83 amino acid C-terminal fragment (C83) and, thus, precludes A&#xE2; formation. In the amyloidogenic pathway, cleavage of APP by &#x3B2;-secretase generates a secreted N-terminal fragment &#x3B2; (sAPP&#x3B2;) and a 99 amino acid C-terminal fragment (C99) (<xref ref-type="fig" rid="pone-0035807-g001">Fig. 1A</xref>) <xref ref-type="bibr" rid="pone.0035807-OBrien1">[24]</xref>. To elucidate whether the D7H mutation shifts the balance between these two pathways, we transiently transfected human embryonic kidney (HEK293) cells with either human wild type (wt) or D7H mutant APP cDNA. The transfection efficiency of both wt and D7H mutant APP are both &#x223C;20% (<xref ref-type="supplementary-material" rid="pone.0035807.s002">Fig. S2A</xref>) and protein expression levels for both wt and D7H mutant APP were similar (<xref ref-type="supplementary-material" rid="pone.0035807.s002">Fig. S2B</xref>). In addition, there is no significant difference in mature/immature APP ratio (<xref ref-type="supplementary-material" rid="pone.0035807.s002">Fig. S2C</xref>). The levels of full length APP, the &#x3B1;-secretase cleavage product C83, and the &#x3B2;-secretase cleavage products C99 and sAPP&#x3B2; were measured by the Western blot. In cells expressing wt APP, the C83 fragment (&#x223C;10 kDa) was the predominant species detected. In cells expressing D7H mutant APP, the C99 fragment (&#x223C;12 kDa) was the predominant species detected (<xref ref-type="fig" rid="pone-0035807-g002">Fig. 2A</xref>). Densitometric analysis revealed that the ratio of C99/C83 in cells expressing D7H mutant APP was 10.3 fold higher than in cells expressing wt APP (<xref ref-type="fig" rid="pone-0035807-g002">Fig. 2A</xref>). Both cells had no significant difference on the level of &#x3B2;&#x2032;-cleavage product C89 (&#x223C;11 kDa). Besides, the level of sAPP&#x3B2; was significant higher in the conditioned media of cells expressing D7H mutant APP than that of cells expressing wt APP (<xref ref-type="fig" rid="pone-0035807-g002">Fig. 2B</xref>). Thus, the D7H mutation may shift APP processing from the non-amyloidogenic to the amyloidogenic cleavage pathway.</p>
        <fig id="pone-0035807-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0035807.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>The D7H mutation increases A&#x3B2; production and the A&#x3B2;42/40 ratio.</title>
            <p>(A&#x2013;C) Western blots were used to monitor the levels of full length APP, the C99 and C83 fragments (A, C) and the sAPP&#x3B2; fragment (B) in HEK293 cells transfected with empty vector (mock), wt APP or D7H mutant APP cDNAs. Densitometric analysis on the right showed a significant increase of the C99/C83 ratio and sAPP&#x3B2; in cells expressing D7H mutant APP in both the absence (A, B) and presence (C) of &#x3B3;-secretase inhibitor L-685,458. (D&#x2013;F) ELISA showed significantly higher fold-change of A&#x3B2;40/APP (D), A&#x3B2;42/APP (E) and A&#x3B2;42/40 (F) in the conditioned media of D7H mutant APP transfected cells. All the data were normalized to data from wt APP-expressing cells (set as 1) in 3 independent experiments (n&#x200A;=&#x200A;3 per experiment) and presented as mean &#xB1; SEM. ***<italic>P</italic>&lt;0.001, *<italic>P</italic>&lt;0.05 by one-way ANOVA and Turkey post-test.</p>
          </caption>
          <graphic xlink:href="pone.0035807.g002"/>
        </fig>
        <p>The higher C99/C83 ratio may be due to either increased C99 production by &#x3B2;-secretase or to delayed C99 removal by &#x3B3;-secretase. To distinguish between these two possibilities, we inhibited &#x3B3;-secretase activity by adding 1 &#x3BC;M L-685,458 to the media for 24 h. The ratio of C99/C83 in cells expressing D7H mutant APP was 5.8 fold higher than in cells expressing wt APP when treated with the inhibitor (<xref ref-type="fig" rid="pone-0035807-g002">Fig. 2C</xref>) but was lower than in cells not treated with inhibitor (10.3 fold). Therefore, both the production and cleavage of C99 were altered by the D7H mutation.</p>
        <p>We next examined whether the D7H mutation alters the extracellular and intracellular A&#x3B2; levels or the A&#x3B2;42/40 ratio. HEK293 cells and conditioned media were both collected at 48 h after APP transfection. A&#x3B2; levels were measured by enzyme-linked immunosorbent assay (ELISA) and normalized to total APP level. The conditioned media of D7H mutant APP transfected culture had 1.5 fold higher extracellular A&#x3B2;40 level and 2.4 fold higher A&#x3B2;42 level compared to that of the wt APP transfected culture (<xref ref-type="fig" rid="pone-0035807-g002">Fig. 2D, E</xref>). Among all variants of A&#x3B2;, A&#x3B2;42 is especially prone to misfolding and aggregating into toxic assemblies <xref ref-type="bibr" rid="pone.0035807-Suzuki1">[7]</xref>, <xref ref-type="bibr" rid="pone.0035807-Zhou1">[8]</xref>. We found that D7H mutant APP transfected culture had a significantly higher ratio of extracellular A&#x3B2;42/40 than the wt APP transfected culture (<xref ref-type="fig" rid="pone-0035807-g002">Fig. 2F</xref>). The accumulation of intracellular A&#x3B2; may also contribute to the pathogenesis of AD. However, we did not find significant differences in intracellular A&#x3B2; levels or in the intracellular A&#x3B2;42/40 ratio between wt APP and D7H mutant APP expressing cells (<xref ref-type="supplementary-material" rid="pone.0035807.s003">Fig. S3</xref>).</p>
      </sec>
      <sec id="s2c">
        <title>The D7H mutation switches the A&#x3B2; aggregation process</title>
        <p>To investigate the effect of the D7H mutation on A&#x3B2; aggregation, we monitored the kinetics of fibril formation, the size distribution and the morphology of A&#x3B2;<sub>wt</sub> and A&#x3B2;<sub>D7H</sub> assemblies by the thioflavin T (ThT) assay, Western blot, and transmission electron microscopy (TEM). Synthetic A&#x3B2; peptides were dissolved in HFIP-DMSO for the Western blot, toxicity and TEM experiments and in guanidine hydrochloride (GdnHCl) for the ThT assay because GdnHCl-denatured A&#x3B2; allows us to better distinguish the kinetics of the early stages of aggregation.</p>
        <sec id="s2c1">
          <title>The D7H mutation promotes A&#x3B2;40 fibril formation</title>
          <p>In the ThT analysis of fibrillization kinetics, the lag time of the initiation of fibril formation for A&#x3B2;40<sub>D7H</sub> (&#x223C;28 h) was longer than that for A&#x3B2;40<sub>wt</sub> (&#x223C;18 h). However, in the saturation phase, the ThT fluorescence intensity of A&#x3B2;40<sub>D7H</sub> was &#x223C;1.5 fold higher than that of A&#x3B2;40<sub>wt</sub> (<xref ref-type="fig" rid="pone-0035807-g003">Fig. 3A</xref>). In order to analyze the size distribution of A&#x3B2; assemblies by Western blot, we used the photo-induced cross-linking of unmodified protein (PICUP) approach to &#x201C;freeze&#x201D; the A&#x3B2; assemblies at indicated time points <xref ref-type="bibr" rid="pone.0035807-Bitan1">[25]</xref>. At the initial time point, both A&#x3B2;40<sub>wt</sub> and A&#x3B2;40<sub>D7H</sub> were predominantly present as low molecular weight (LMW) assemblies (<xref ref-type="fig" rid="pone-0035807-g003">Fig. 3C</xref>). After 96 h of incubation, more A&#x3B2;40<sub>D7H</sub> than A&#x3B2;40<sub>wt</sub> aggregated into high molecular weight (HMW) assemblies. Here, we defined the A&#x3B2; assemblies that can be separated by 15% Tricine-PAGEs as LMW (usually below 78 kDa) while the larger A&#x3B2; assemblies retaining in stacking gel as HMW. Using TEM, we observed more fibrillar structures in the A&#x3B2;40<sub>D7H</sub> assemblies and more oligomeric or protofibrillar structures in the A&#x3B2;40<sub>wt</sub> assemblies after 312 h of incubation (<xref ref-type="fig" rid="pone-0035807-g004">Fig. 4</xref>). All of these experiments indicate that the D7H mutation slightly delays A&#x3B2; nucleation and promotes the formation of A&#x3B2;40 HMW assemblies and fibrils.</p>
          <fig id="pone-0035807-g003" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pone.0035807.g003</object-id>
            <label>Figure 3</label>
            <caption>
              <title>The D7H mutation promotes A&#x3B2;40 HMW assemblies and A&#x3B2;42 LMW assemblies formation.</title>
              <p>Lyophilized A&#x3B2; was prepared in GdnHCl for the ThT assay (A, B) or in HFIP-DMSO for Western blot (C, D), and samples were collected at indicated times. (A, B) The ThT assay was applied to monitor the kinetics of &#x3B2;-sheet formation for A&#x3B2;40<sub>wt</sub> (A,&#x2022;), A&#x3B2;40<sub>D7H</sub> (A,&#x25CB;), A&#x3B2;42<sub>wt</sub> (B,&#x2022;) and A&#x3B2;42<sub>D7H</sub> (B,&#x25CB;). Data were averaged from 3&#x2013;4 independent experiments (n&#x200A;=&#x200A;3 per experiment). (C) A&#x3B2;40 and (D) A&#x3B2;42 samples were fixed by PICUP and examined by Western blot to analyze the size distribution of assemblies during aggregation.</p>
            </caption>
            <graphic xlink:href="pone.0035807.g003"/>
          </fig>
          <fig id="pone-0035807-g004" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pone.0035807.g004</object-id>
            <label>Figure 4</label>
            <caption>
              <title>A&#x3B2; morphology in the presence or absence of metal ions was revealed by TEM.</title>
              <p>Lyophilized A&#x3B2; was prepared in HFIP-DMSO. After 264&#x2013;312 h of incubation in either the presence or absence of Zn<sup>2+</sup> or Cu<sup>2+</sup>, the A&#x3B2; samples were stained by 2% uranyl acetate and monitored by TEM. In the presence of ions, the A&#x3B2;<sub>D7H</sub> peptides were predominantly amorphous morphology but not protofibrils as A&#x3B2;<sub>wt</sub>. Scale bar: 200 nm.</p>
            </caption>
            <graphic xlink:href="pone.0035807.g004"/>
          </fig>
        </sec>
        <sec id="s2c2">
          <title>The D7H mutation promotes A&#x3B2;42 LMW assembly formation</title>
          <p>Next, we studied the effect of the D7H mutation on A&#x3B2;42 aggregation using the same approaches as described above for A&#x3B2;40. Unexpectedly, the D7H mutation did not promote the formation of A&#x3B2;42 fibrils but rather prolonged the duration of A&#x3B2;42 oligomers.</p>
          <p>In the ThT analysis of fibrillization kinetics, the lag time of the initiation of fibril formation for A&#x3B2;42<sub>D7H</sub> (&#x223C;58 h) was longer than that for A&#x3B2;42<sub>wt</sub> (&#x223C;18 h). In the saturation phase, the ThT fluorescence intensity of A&#x3B2;42<sub>D7H</sub> was &#x223C;1.35 fold lower than that of A&#x3B2;42<sub>wt</sub> (<xref ref-type="fig" rid="pone-0035807-g003">Fig. 3B</xref>). In the Western blot analysis, A&#x3B2;42<sub>wt</sub> quickly aggregated into HMW assemblies after 48 h while A&#x3B2;42<sub>D7H</sub> remained in LMW assemblies until 192 h when it gradually aggregated into HMW assemblies (<xref ref-type="fig" rid="pone-0035807-g003">Fig. 3D</xref>). Using TEM, we observed more oligomeric or protofibrillar structures in the A&#x3B2;42<sub>D7H</sub> assemblies and more fibrillar structures in the A&#x3B2;42<sub>wt</sub> assemblies after 312 h of incubation (<xref ref-type="fig" rid="pone-0035807-g004">Fig. 4</xref>). All of these results indicate that the D7H mutation results in A&#x3B2;42 remaining in LMW assemblies longer and in reduced HMW fibril formation.</p>
          <p>Considering that the GdnHCl in our A&#x3B2; preparation might affect the assembly state <xref ref-type="bibr" rid="pone.0035807-Glabe1">[4]</xref>, the results of the ThT assay were also confirmed by preparing A&#x3B2; in HFIP-DMSO (<xref ref-type="supplementary-material" rid="pone.0035807.s004">Fig. S4A</xref>, B). In this condition, the D7H mutation also increased A&#x3B2;40 fibril formation and decreased A&#x3B2;42 fibril formation. Considering the possibility that artificial assemblies may be induced by PICUP, Western blot analysis without PICUP was also performed (<xref ref-type="supplementary-material" rid="pone.0035807.s004">Fig. S4C, D</xref>). These results also confirmed that the D7H mutation promotes the formation of A&#x3B2;40 HMW assemblies and prolongs the time A&#x3B2;42 remains in LMW assemblies.</p>
        </sec>
      </sec>
      <sec id="s2d">
        <title>The D7H mutation promotes A&#x3B2;42 neurotoxicity</title>
        <p>Because the oligomers are generally considered to be the more neurotoxic A&#x3B2; assembly state, the increase of A&#x3B2;42<sub>D7H</sub> oligomers may promote neurotoxicity. To determine the effect of the D7H mutation on the neurotoxicity of A&#x3B2;42 oligomers, synthetic A&#x3B2;42<sub>wt</sub> and A&#x3B2;42<sub>D7H</sub> were prepared using HFIP-DMSO and incubated at 4&#xB0;C for 24 h. The neurotoxicity of these A&#x3B2;42 assemblies on SH-SY5Y human neuroblastoma cells was measured using the MTT assay. After 48 h of co-incubation with either 5 &#x3BC;M or 10 &#x3BC;M A&#x3B2;42<sub>D7H</sub>, SH-SY5Y cells had significantly lower survival rates than cells incubated with A&#x3B2;42<sub>wt</sub> (<xref ref-type="fig" rid="pone-0035807-g005">Fig. 5</xref>). Our results indicate that the D7H mutation promotes neurotoxicity of A&#x3B2;42.</p>
        <fig id="pone-0035807-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0035807.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>The D7H mutation enhances the neurotoxicity of A&#x3B2;42.</title>
            <p>The neurotoxicities of A&#x3B2;42<sub>wt</sub> and A&#x3B2;42<sub>D7H</sub> were estimated by the MTT assay. SH-SY5Y cells were treated with A&#x3B2;42<sub>wt</sub> or A&#x3B2;42<sub>D7H</sub> at a final concentration of 0, 5, or 10 &#x3BC;M for 48 h. Cell survival was determined by normalizing OD570 readings to those of cells not treated with A&#x3B2;42 (set as 1) in 3 independent experiments (n&#x200A;=&#x200A;8 per experiment) and is presented as mean &#xB1; SEM. ***<italic>P</italic>&lt;0.001, **<italic>P</italic>&lt;0.01 vs. A&#x3B2;42<sub>wt</sub> by ANOVA.</p>
          </caption>
          <graphic xlink:href="pone.0035807.g005"/>
        </fig>
        <p>Together, this mutation increased A&#x3B2; production, A&#x3B2;42/A&#x3B2;40 ratio, and prolonged A&#x3B2;?2 oligomer state with higher neurotoxicity. Therefore, we propose to classify the D7H mutation as probable pathogenic according to the algorithm proposed previously <xref ref-type="bibr" rid="pone.0035807-Guerreiro1">[26]</xref>.</p>
      </sec>
      <sec id="s2e">
        <title>The D7H mutation alters the biochemical features of ion-induced A&#x3B2; assemblies</title>
        <p>Histidines at the 6<sup>th</sup>, 13<sup>th</sup> and 14<sup>th</sup> residues of A&#x3B2; are important for the peptide's interaction with the metal ions, which can also affect A&#x3B2; aggregation <xref ref-type="bibr" rid="pone.0035807-Minicozzi1">[19]</xref>, <xref ref-type="bibr" rid="pone.0035807-Nair1">[20]</xref>. We speculated that the appearance of one more histidine at the 7<sup>th</sup> residue of A&#x3B2;<sub>D7H</sub> may enhance susceptibility to the effect of Zn<sup>2+</sup> or Cu<sup>2+</sup> on A&#x3B2; aggregation. To explore this speculation, we incubated A&#x3B2;<sub>wt</sub> or A&#x3B2;<sub>D7H</sub> with Zn<sup>2+</sup> or Cu<sup>2+</sup> to observe the kinetics of fibril formation, size distribution, and morphology of the respective A&#x3B2; assemblies.</p>
        <p>For the ThT assay, A&#x3B2; was incubated with Zn<sup>2+</sup> or Cu<sup>2+</sup> in 1&#x2236;1, 2&#x2236;1 and 5&#x2236;1 (A&#x3B2;: metal ion) ratios for 80&#x2013;150 h. We found that Zn<sup>2+</sup> accelerated while Cu<sup>2+</sup> prolonged initiation of A&#x3B2;40<sub>wt</sub> aggregation as we reported previously <xref ref-type="bibr" rid="pone.0035807-Chen1">[27]</xref>. Both ions had stronger inhibitory effects on fibril formation in A&#x3B2;40<sub>D7H</sub> than in A&#x3B2;40<sub>wt</sub> in a dose dependent manner. At a 1&#x2236;1 ratio with Zn<sup>2+</sup>, the ThT intensity in the saturation phase of A&#x3B2;40<sub>wt</sub> was 10% lower than that of the no ion control while A&#x3B2;40<sub>D7H</sub> was 90% lower than that of the no ion control (<xref ref-type="fig" rid="pone-0035807-g006">Fig. 6A, C</xref>). At a 1&#x2236;1 ratio with Cu<sup>2+</sup>, the ThT intensity of A&#x3B2;40<sub>wt</sub> was 50% lower than that of the no ion control while A&#x3B2;40<sub>D7H</sub> was &#x223C;100% lower than that of the no ion control (<xref ref-type="fig" rid="pone-0035807-g006">Fig. 6B, D</xref>). These 2 ions also had stronger inhibitory effects on A&#x3B2;42 fibril formation for A&#x3B2;42<sub>D7H</sub> than for A&#x3B2;42<sub>wt</sub>. Cu<sup>2+</sup> inhibited fibril formation in A&#x3B2;42<sub>D7H</sub> to a greater extent than in A&#x3B2;42<sub>wt</sub>, but Zn<sup>2+</sup>-induced inhibition was similar for A&#x3B2;42<sub>wt</sub> and A&#x3B2;42<sub>D7H</sub> in the ThT assay (<xref ref-type="fig" rid="pone-0035807-g006">Fig. 6E&#x2013;H</xref>).</p>
        <fig id="pone-0035807-g006" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0035807.g006</object-id>
          <label>Figure 6</label>
          <caption>
            <title>The D7H mutation shifts Zn<sup>2+</sup> and Cu<sup>2+</sup>-induced assemblies toward smaller oligomers with fewer fibrils.</title>
            <p>(A&#x2013;H) 25 &#x3BC;M A&#x3B2; was incubated with 25 &#x3BC;M ThT in Tris buffer containing 0 &#x3BC;M (black), 5 &#x3BC;M (light color), 12.5 &#x3BC;M (medium color) or 25 &#x3BC;M (dark color) of Zn<sup>2+</sup> (red) or Cu<sup>2+</sup> (blue). (A) A&#x3B2;40<sub>wt</sub> + Zn<sup>2+</sup>, (B) A&#x3B2;40<sub>wt</sub> + Cu<sup>2+</sup>, (C) A&#x3B2;40<sub>D7H</sub> + Zn<sup>2+</sup>, (D) A&#x3B2;40<sub>D7H</sub> + Cu<sup>2+</sup>, (E) A&#x3B2;42<sub>wt</sub> + Zn<sup>2+</sup>, (F) A&#x3B2;42<sub>wt</sub> + Cu<sup>2+</sup>, (G) A&#x3B2;42<sub>D7H</sub> + Zn<sup>2+</sup>, (H) A&#x3B2;42<sub>D7H</sub> + Cu<sup>2+</sup>. (I&#x2013;J) 25 &#x3BC;M A&#x3B2;40 (I) and A&#x3B2;42 (J) were co-incubated with 25 &#x3BC;M Zn<sup>2+</sup> or Cu<sup>2+</sup> for 114 h, fixed by PICUP and examined by Western blot to analyze the size distribution.</p>
          </caption>
          <graphic xlink:href="pone.0035807.g006"/>
        </fig>
        <p>In the Western blot analysis, A&#x3B2; was incubated with Zn<sup>2+</sup> or Cu<sup>2+</sup> at a 1&#x2236;1 ratio for 144 h. We found that A&#x3B2;40<sub>wt</sub> aggregated into mostly LMW assemblies with or without ions. However, when A&#x3B2;40<sub>D7H</sub> was co-incubated with Zn<sup>2+</sup> or Cu<sup>2+</sup><sub>,</sub> we observed fewer HMW assemblies and more LMW assemblies than in the no ion control (<xref ref-type="fig" rid="pone-0035807-g006">Fig. 6I</xref>). Similar to our findings in <xref ref-type="fig" rid="pone-0035807-g003">figure 3D</xref>, both A&#x3B2;42<sub>wt</sub> and A&#x3B2;42<sub>D7H</sub> aggregated into HMW assemblies in the no ion controls after 144 h. When A&#x3B2;42<sub>wt</sub> or A&#x3B2;42<sub>D7H</sub> was co-incubated with Zn<sup>2+</sup><sub>,</sub> we observed fewer HMW assemblies and more LMW assemblies than in the no ion control. However, when A&#x3B2;42<sub>D7H</sub>, but not A&#x3B2;42<sub>wt</sub>, was co-incubated with Cu<sup>2+</sup><sub>,</sub> we observed fewer HMW assemblies and more LMW assemblies than in the no ion control (<xref ref-type="fig" rid="pone-0035807-g006">Fig. 6J</xref>). The Western blot results are consistent with those of the ThT assay, indicating that the A&#x3B2;<sub>D7H</sub> mutation shifts the sizes distribution of ion-induced A&#x3B2; oligomers into LMW assemblies.</p>
        <p>For the TEM observations, A&#x3B2; was incubated with Zn<sup>2+</sup> or Cu<sup>2+</sup> in a 1&#x2236;1 ratio for 264&#x2013;312 h. After incubation with Zn<sup>2+</sup>, we found that the A&#x3B2;<sub>wt</sub> assemblies were predominantly annular protofibrils as we reported previously but the A&#x3B2;<sub>D7H</sub> assemblies mostly had an amorphous morphology (<xref ref-type="fig" rid="pone-0035807-g004">Fig. 4</xref>). After incubation with Cu<sup>2+</sup>, the A&#x3B2;<sub>wt</sub> assemblies were predominantly protofibrils and short fibrils. However, the A&#x3B2;<sub>D7H</sub> assemblies were predominantly amorphous with occasional short fibrils (<xref ref-type="fig" rid="pone-0035807-g004">Fig. 4</xref>). The TEM results indicate that not only the size but also the morphology of ion-induced A&#x3B2; oligomers are altered by the D7H mutation.</p>
      </sec>
      <sec id="s2f">
        <title>The D7H mutation promotes the interaction of Zn<sup>2+</sup> and Cu<sup>2+</sup> with A&#x3B2;</title>
        <p>Our result suggests a higher susceptibility of A&#x3B2;<sub>D7H</sub> to Zn<sup>2+</sup>/Cu<sup>2+</sup> during aggregation process. To access a more direct evidence of A&#x3B2;-ion interaction, we used Bis-ANS <xref ref-type="bibr" rid="pone.0035807-Chen1">[27]</xref>, <xref ref-type="bibr" rid="pone.0035807-LeVine1">[28]</xref> to probe A&#x3B2; conformation at early aggregation stage in the presence or absence of ions to estimate the binding affinity of A&#x3B2;-ion complex. The 490 nm fluorescence signals of 50 &#x3BC;M A&#x3B2; in the presence of varying concentrations of Zn<sup>2+</sup> or Cu<sup>2+</sup> were collected. The final titration signal of each condition was used as unit for normalization (<xref ref-type="fig" rid="pone-0035807-g007">Fig. 7</xref>). Fluorescence signals without normalization are shown in <xref ref-type="supplementary-material" rid="pone.0035807.s005">figure S5</xref>. The Bis-ANS emission of A&#x3B2;40<sub>wt</sub> and A&#x3B2;40<sub>D7H</sub> had &#x223C;6.5- and &#x223C;11.5-fold increase in the presence of Zn<sup>2+</sup> (<xref ref-type="supplementary-material" rid="pone.0035807.s005">Fig. S5A, C</xref>) but had &#x223C;1.5- and &#x223C;2.4-fold decrease in the presence of Cu<sup>2+</sup> (<xref ref-type="supplementary-material" rid="pone.0035807.s005">Fig. S5B, D</xref>). Thus, at early aggregation stage, the D7H mutation exaggerated the ion-induced A&#x3B2;40 structural changes with Zn<sup>2+</sup> increasing but Cu<sup>2+</sup> decreasing exposure of hydrophobic clusters. For the Zn<sup>2+</sup> titration, saturation of structural changes occurred at around 200 &#x3BC;M Zn<sup>2+</sup> for A&#x3B2;40<sub>wt</sub> (Zn<sup>2+</sup>: A&#x3B2; as 4&#x2236;1) and at around 5 &#x3BC;M Zn<sup>2+</sup> for A&#x3B2;40<sub>D7H</sub> (Zn<sup>2+</sup>: A&#x3B2; as 1&#x2236;10, <xref ref-type="fig" rid="pone-0035807-g007">Fig. 7A</xref>). For the Cu<sup>2+</sup> titration, saturation of structural changes occurred at around 10 &#x3BC;M Cu<sup>2+</sup> for A&#x3B2;40<sub>wt</sub> (Cu<sup>2+</sup>: A&#x3B2; as 1&#x2236;5) and at around 5 &#x3BC;M Cu<sup>2+</sup> for A&#x3B2;40<sub>D7H</sub> (Cu<sup>2+</sup>: A&#x3B2; as 1&#x2236;10, <xref ref-type="fig" rid="pone-0035807-g007">Fig. 7B</xref>). Our result indicates that the D7H mutation promotes A&#x3B2;40 interaction with Zn<sup>2+</sup> and Cu<sup>2+</sup>, where the A&#x3B2; interaction with Zn<sup>2+</sup> is especially enhanced by the mutation.</p>
        <fig id="pone-0035807-g007" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0035807.g007</object-id>
          <label>Figure 7</label>
          <caption>
            <title>The D7H mutation promotes the binding of Zn<sup>2+</sup> and Cu<sup>2+</sup> to A&#x3B2;.</title>
            <p>The structural changes of 50 &#x3BC;M A&#x3B2;40<sub>wt</sub> (&#x25AA;) or A&#x3B2;40<sub>D7H</sub> (&#x25A1;) during 0 to 20 &#x3BC;M Zn<sup>2+</sup> (A) and Cu<sup>2+</sup> (B) titration were monitored by 5 &#x3BC;M Bis-ANS. (A inlet) A&#x3B2;40<sub>wt</sub> (&#x25AA;) and A&#x3B2;40<sub>D7H</sub> (&#x25A1;) were titrated by 0 to 200 &#x3BC;M Zn<sup>2+</sup>. The signals at 490 nm of Bis-ANS fluorescence were normalized and plotted to ion concentration. Data were presented as mean &#xB1; SEM from 3 independent experiments.</p>
          </caption>
          <graphic xlink:href="pone.0035807.g007"/>
        </fig>
      </sec>
      <sec id="s2g">
        <title>The D7H mutation has lower redox activity</title>
        <p>The redox activity of A&#x3B2; has been suggested to play a role in neurotoxicity and oligomerization process. Altered redox activity may be one of the mechanisms underlying our findings. Thus, we examined the redox activity of A&#x3B2;42<sub>wt</sub> and A&#x3B2;42<sub>D7H</sub> by metal reduction assay with bicinchoninic acid (<xref ref-type="fig" rid="pone-0035807-g008">Fig. 8</xref>) <xref ref-type="bibr" rid="pone.0035807-Huang1">[29]</xref>. The reaction provides a quantitative method for Cu<sup>+</sup> production representing the capability of A&#x3B2; to reduce Cu<sup>2+</sup> to Cu<sup>+</sup>. Our result demonstrated that A&#x3B2;42<sub>D7H</sub> has &#x223C;45% lower Cu<sup>+</sup> production in comparison to that of A&#x3B2;42<sub>wt</sub>. The lower capability of A&#x3B2;42<sub>D7H</sub> to reduce Cu<sup>2+</sup> to Cu<sup>+</sup> suggested a lower redox activity of A&#x3B2;42<sub>D7H</sub> than A&#x3B2;42<sub>wt</sub>.</p>
        <fig id="pone-0035807-g008" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0035807.g008</object-id>
          <label>Figure 8</label>
          <caption>
            <title>The D7H mutation decreases the redox activity of A&#x3B2;42 in metal reduction assay.</title>
            <p>Reduction of Cu<sup>2+</sup> to Cu<sup>+</sup> was performed by BCA assay. Freshly prepared 10 &#x3BC;M A&#x3B2;42<sub>wt</sub> and A&#x3B2;42<sub>D7H</sub> were mixed with BCA solution containing 4% CuSO<sub>4</sub> to perform the redox activity assay. Data were presented as mean &#xB1; SEM (n&#x200A;=&#x200A;3), ***<italic>P</italic>&lt;0.0001.</p>
          </caption>
          <graphic xlink:href="pone.0035807.g008"/>
        </fig>
      </sec>
    </sec>
    <sec id="s3">
      <title>Discussion</title>
      <p>In this study, we report a novel intra-A&#x3B2; mutation, A&#x3B2;<sub>D7H</sub>, which has a &#x201C;double punch&#x201D; effect on the disease progress of AD by modulating both A&#x3B2;production and oligomer formation.</p>
      <p>APP overexpressing cell culture study indicated that the D7H mutation enhances the amyloidogenic cleavage pathway and raises A&#x3B2; production and the A&#x3B2;42/40 ratio. In vitro examination indicated that the D7H mutation shifts A&#x3B2;40 aggregation into the fibril-prone pathway and A&#x3B2;42 aggregation into the oligomer-prone pathway. According to the algorithm proposed by Guerreiro to classify AD mutations, we consider that this D7H mutation could be classified as &#x201C;probably pathogenic&#x201D; <xref ref-type="bibr" rid="pone.0035807-Guerreiro1">[26]</xref>.</p>
      <p>In addition, we characterized the biochemical features of A&#x3B2;<sub>D7H</sub>-ion complex, including the kinetic of fibril formation, size distribution, morphology and binding affinity. Our results of A&#x3B2;<sub>wt</sub>-ion are all compatible with others <xref ref-type="bibr" rid="pone.0035807-Chen1">[27]</xref>, <xref ref-type="bibr" rid="pone.0035807-Tougu1">[30]</xref>, <xref ref-type="bibr" rid="pone.0035807-Tougu2">[31]</xref>, <xref ref-type="bibr" rid="pone.0035807-Pedersen1">[32]</xref>. Therefore, we provide an index of the biochemical features of A&#x3B2;-ion complex with a genetic hint, which might be more relevant to AD pathogenesis. Our study may contribute to the knowledge of designing A&#x3B2;-ion interrupting therapy in AD.</p>
      <sec id="s3a">
        <title>The effect of intra-A&#x3B2; mutations on APP processing</title>
        <p>Shifting APP processing into amyloidgenic pathway is one of the key factors in AD pathogenesis <xref ref-type="bibr" rid="pone.0035807-OBrien1">[24]</xref>. We speculated that the increase in A&#x3B2; levels and A&#x3B2;42/40 ratio of D7H mutant APP may accelerate A&#x3B2; accumulation in the brain. Usually, intra-A&#x3B2; mutations are less prone to interfere with APP processing. Only the A2V, E11K, and A21G mutations enhance amyloidogenic cleavage <xref ref-type="bibr" rid="pone.0035807-Zhou1">[8]</xref>, <xref ref-type="bibr" rid="pone.0035807-DiFede1">[33]</xref>, <xref ref-type="bibr" rid="pone.0035807-DeJonghe1">[34]</xref>. Interestingly, the D7N Tottori mutation does not affect A&#x3B2; levels or the A&#x3B2;42/40 ratio in the conditioned media of stably transfected N2a cells <xref ref-type="bibr" rid="pone.0035807-Hori1">[14]</xref>. Besides the &#x3B2;-site cleavage to generate the C99 fragment, &#x3B2;-secretase could also cleave APP at the &#x3B2;&#x2032;-site between Tyr10 and Glu11 to generate an 89 amino acid fragment (C89). The E11K mutation blocks the &#x3B2;&#x2032;-site and shifts cleavage of APP to the &#x3B2;-site, causing increased A&#x3B2; production <xref ref-type="bibr" rid="pone.0035807-Zhou1">[8]</xref>. In this study, we did not detect significant differences in C89 level between wt APP and D7H mutant APP expressing cells, indicating that the D7H mutation does not interfere with &#x3B2;&#x2032; cleavage of APP.</p>
        <p>Moreover, APP processing and trafficking could be regulated by imbalance of copper or zinc <xref ref-type="bibr" rid="pone.0035807-Phinney1">[35]</xref>, <xref ref-type="bibr" rid="pone.0035807-Acevedo1">[36]</xref>, <xref ref-type="bibr" rid="pone.0035807-Zheng1">[37]</xref>, <xref ref-type="bibr" rid="pone.0035807-Wang1">[38]</xref>. Zn<sup>2+</sup> and Cu<sup>2+</sup> also bind to the E1 and E2 domain at N-terminal APP. Metal binding to E1 domain is related to the iron transport and APP ferroxidase-like activity <xref ref-type="bibr" rid="pone.0035807-Duce2">[39]</xref>. Metal binding to E2 domain is suggested to relate with APP processing <xref ref-type="bibr" rid="pone.0035807-Dahms1">[40]</xref>. However, whether D7H changes metal binding to APP and alters APP structure, function and processing remains unclear. The mechanism by which D7H mutant APP favors the amyloidogenic cleavage pathway needs further investigation.</p>
      </sec>
      <sec id="s3b">
        <title>The role of the A&#x3B2; N-terminal region in aggregation and toxicity</title>
        <p>Similar to most of the intra-A&#x3B2; mutants, the A&#x3B2;42<sub>D7H</sub> mutant induced more cell death than A&#x3B2;42<sub>wt</sub>, suggesting that the D7H mutation-induced aggregates are neurotoxic. The D7H mutation may increase toxicity through its effects on the duration of A&#x3B2; oligomer formation or on the structures of the aggregates thus formed. However, the SH-SY5Y cell might not be a good model of neurotoxic effect of A&#x3B2; as A&#x3B2;42<sub>wt</sub> showing only a trend of toxicity (<xref ref-type="fig" rid="pone-0035807-g005">Fig. 5</xref>). For future studies, the pathological role of A&#x3B2;<sub>D7H</sub> should be confirmed in primary culture, brain slices, or D7H mutant APP transgenic mice.</p>
        <p>To our surprise, the D7H mutation had distinct effects on A&#x3B2;40 and A&#x3B2;42 fibrillization, which has not been reported for other intra-A&#x3B2; mutations. The fibrogenic properties of A&#x3B2;42 are signed by two additional residues, Ile41 and Ala42, altering its structure and hydrophobicity <xref ref-type="bibr" rid="pone.0035807-Schmidt1">[41]</xref>. Nevertheless, an additional secondary structure between the Phe4-His14 region is found in A&#x3B2;40 but not A&#x3B2;42 fibrils <xref ref-type="bibr" rid="pone.0035807-Olofsson1">[42]</xref>. The D7H mutation, which is located in this region, may have distinct effects on the aggregation properties of A&#x3B2;40 and A&#x3B2;42 by altering this N-terminal structure. This A&#x3B2;<sub>D7H</sub> mutant provides an interesting tool for further biochemical study of the effect of the N-terminal region on the differential aggregation properties of A&#x3B2;40 and A&#x3B2;42.</p>
      </sec>
      <sec id="s3c">
        <title>Effect of metal ions on A&#x3B2; aggregation</title>
        <p>The high concentration of Zn<sup>2+</sup> or Cu<sup>2+</sup> in glutamatergic synapses has been proposed to promote A&#x3B2; aggregation and toxicity <xref ref-type="bibr" rid="pone.0035807-Duce1">[21]</xref>. Interrupting A&#x3B2;-ion interaction with a metal-protein-attenuating compound, PBT2, has beneficial effects in the AD mouse model and in the phase II clinical trial <xref ref-type="bibr" rid="pone.0035807-Faux1">[22]</xref>. We speculate that the pathogenicity of A&#x3B2;<sub>D7H</sub> might be partially contributed by its higher affinity toward Zn<sup>2+</sup>/Cu<sup>2+</sup> (<xref ref-type="fig" rid="pone-0035807-g007">Fig. 7</xref>). Consistent with this speculation, we show that the D7H mutation exaggerated the Zn<sup>2+</sup>/Cu<sup>2+</sup>-induced A&#x3B2; conformational changes (<xref ref-type="supplementary-material" rid="pone.0035807.s005">Fig. S5</xref>). The opposite effect of Zn<sup>2+</sup> and Cu<sup>2+</sup> on A&#x3B2; conformation at early aggregation stage has also been shown in our previous study <xref ref-type="bibr" rid="pone.0035807-Chen1">[27]</xref>.</p>
        <p>Cu<sup>2+</sup> has been shown to inhibit A&#x3B2; fibrillization and to induce assemblies with multiple morphologies <xref ref-type="bibr" rid="pone.0035807-Chen1">[27]</xref>, <xref ref-type="bibr" rid="pone.0035807-Dai1">[43]</xref>, <xref ref-type="bibr" rid="pone.0035807-Shin1">[44]</xref>. The altered properties of A&#x3B2;<sub>D7H</sub>-Cu<sup>2+</sup> complex might be the result of Cu<sup>2+</sup> interaction with the additional histidines at A&#x3B2; position 7. Most of the free Cu<sup>2+</sup> interacting with His6/His13 or His6/His14 promotes &#x3B2;-sheet-rich fibril formation, while a small proportion of Cu<sup>2+</sup> interacting with the adjacent imidazole rings at His13/His14 inhibits fibril but promotes &#x201C;amorphous&#x201D; structure formation <xref ref-type="bibr" rid="pone.0035807-Shin1">[44]</xref>, <xref ref-type="bibr" rid="pone.0035807-Karr1">[45]</xref>. Therefore, we speculate that the additional two adjacent imidazole rings at His6/His7 of A&#x3B2;<sub>D7H</sub> promote the formation of &#x201C;amorphous&#x201D; non-&#x3B2;-sheet assemblies.</p>
        <p>Zn<sup>2+</sup> has been shown to inhibit fibril but to promote annular protofibril formation of A&#x3B2;<sub>wt</sub>
<xref ref-type="bibr" rid="pone.0035807-Chen1">[27]</xref>, <xref ref-type="bibr" rid="pone.0035807-Bush1">[46]</xref>. In this study, Zn<sup>2+</sup> promoted &#x201C;amorphous&#x201D; assemblies formation of A&#x3B2;<sub>D7H</sub>. Computational studies revealed that Asp7 is important for the stabilization of Zn<sup>2+</sup>-induced oligomers <xref ref-type="bibr" rid="pone.0035807-Miller1">[47]</xref>. Therefore, we speculate that the loss of Asp7 in A&#x3B2;<sub>D7H</sub> destabilize Zn<sup>2+</sup>-induced annular protofibril and thus promote &#x201C;amorphous&#x201D; aggregate formation. Together, our findings suggest that the &#x201C;amorphous&#x201D; aggregates induced by Zn<sup>2+</sup>/Cu<sup>2+</sup> might be more relevant to AD pathology.</p>
        <p>Mutations in 21<sup>st</sup>&#x2013;23<sup>rd</sup> residues of A&#x3B2; showed no differences in ion-induced aggregation while the ion-induced aggregation of A&#x3B2; N-terminus mutations has not been examined <xref ref-type="bibr" rid="pone.0035807-Clements1">[48]</xref>. Our results provide the first genetic indication linking Zn<sup>2+</sup> and Cu<sup>2+</sup>-induced A&#x3B2; aggregation to the pathogenesis of AD.</p>
      </sec>
      <sec id="s3d">
        <title>Redox activity of A&#x3B2;</title>
        <p>The histidine residues on A&#x3B2; are thought to play a role in controlling the redox activity of Cu<sup>2+</sup>
<xref ref-type="bibr" rid="pone.0035807-Nakamura1">[49]</xref>. In our study, although A&#x3B2;<sub>D7H</sub> had higher Cu<sup>2+</sup> binding affinity (<xref ref-type="fig" rid="pone-0035807-g007">Fig. 7</xref>), A&#x3B2;<sub>D7H</sub> had lower capability to reduce Cu<sup>2+</sup> to Cu<sup>+</sup> (<xref ref-type="fig" rid="pone-0035807-g008">Fig. 8</xref>). This indicates that the redox activity of A&#x3B2;-Cu<sup>2+</sup> might be controlled by multiple factors rather than be simply controlled by the Cu<sup>2+</sup> binding affinity. Redox activity has been suggested to involve in the A&#x3B2;-induced cytotoxicity and oligomerization <xref ref-type="bibr" rid="pone.0035807-Smith1">[18]</xref>, <xref ref-type="bibr" rid="pone.0035807-Barnham1">[50]</xref>. Lower redox activity of A&#x3B2;42<sub>D7H</sub> suggested that redox activity is not the primary factor for A&#x3B2;42<sub>D7H</sub>-induced cytotoxicity. Furthermore, A&#x3B2;-Cu<sup>+</sup> complex is suggested to promote cross-linking of peptides through dityrosine formation to stabilize oligomers <xref ref-type="bibr" rid="pone.0035807-Smith2">[51]</xref>, <xref ref-type="bibr" rid="pone.0035807-Atwood1">[52]</xref>. Nevertheless, A&#x3B2;42<sub>D7H</sub> had lower Cu<sup>+</sup> production (<xref ref-type="fig" rid="pone-0035807-g008">Fig. 8</xref>) but retained aggregates in LMW oligomers (<xref ref-type="fig" rid="pone-0035807-g006">Fig. 6</xref>), indicating that the A&#x3B2;42<sub>D7H</sub> LMW oligomers might not be stabilized by dityrosine formation or redox activity. Together, the change in redox activity might not be the mechanism underlying our findings, but more details of redox activity other than copper reduction should be addressed.</p>
      </sec>
    </sec>
    <sec sec-type="methods" id="s4">
      <title>Methods</title>
      <sec id="s4a">
        <title>Human subject and cell line information</title>
        <p>This study was approved by Institutional Review Board at Taipei Veterans General Hospital. The written informed consent was obtained from the patient. The patient's guardian also consented on the behalf her because her capacity to consent was reduced. Human embryonic kidney (HEK293) cells were from Bioresource Collection and Research Center (60019, Hsinchu, Taiwan). SH-SY5Y human neuroblastoma cells were from Sigma-Aldrich (94030304, MO, USA).</p>
      </sec>
      <sec id="s4b">
        <title>Materials</title>
        <p>Metal ions were all prepared in double-distilled Mill-Q water. Purchasing information for all the materials used in this study is listed in supplementary materials (<xref ref-type="supplementary-material" rid="pone.0035807.s006">Method S1</xref>).</p>
      </sec>
      <sec id="s4c">
        <title>Plasmid construction</title>
        <p>cDNA encoding human wild-type hAPP770 was subcloned into a CMV promoter/enhancer-driven expression vector (pDEST26). A QuickChange II site-directed mutagenesis kit was used to introduce the D7H mutation into the wt APP construct. The correctness of the resulting constructs was confirmed by sequence analysis.</p>
      </sec>
      <sec id="s4d">
        <title>Cell culture</title>
        <p>Human embryonic kidney (HEK293) cells were transfected with the wt APP and the D7H mutant APP plasmids by Lipofectamin 2000 according to the manufacturer's protocol. 36 hours after transfection, cells were lysed with Trizol reagent to isolate total protein following the manufacturer's instruction.</p>
      </sec>
      <sec id="s4e">
        <title>APP and A&#x3B2; measurement</title>
        <p>To determine the levels of full length APP and the C-terminal fragments, 70 &#x3BC;g (<xref ref-type="fig" rid="pone-0035807-g002">Fig. 2A</xref>) and 30 &#x3BC;g (<xref ref-type="fig" rid="pone-0035807-g002">Fig. 2C</xref>) of cell lysates were separated by 15% Tris-Tricine SDS-PAGE and analyzed with a mouse anti-APP N-terminus antibody (22C11) or rabbit anti-APP C-terminus antibody (AB5352). To measure sAPP&#x3B2;, conditioned media of APP expression cells were separated by 8% Tris-glycine SDS-PAGE and analyzed with a rabbit anti-sAPP&#x3B2; antibody (9138-005). To monitor A&#x3B2; assemblies, the cross-linked samples were separated by 4%, 10%, and 15% stacking Tris-Tricine SDS-PAGE, and analyzed with an anti-A&#x3B2; 17&#x2013;24 antibody (4G8). Human A&#x3B2; levels in APP transfected cells were quantitated by enzyme-linked immunosorbent assay (ELISA) using high sensitivity human &#x3B2; Amyloid 40 and 42 kits that use anti-Human A&#x3B2; 11&#x2013;28 as the capture antibody. All antibodies used in this study do not recognize A&#x3B2;-Asp7 as an epitope.</p>
      </sec>
      <sec id="s4f">
        <title>A&#x3B2; preparation</title>
        <p>A&#x3B2; peptides were synthesized using Fmoc (N-(9-fluorenyl) methoxycarbonyl) chemistry and purified by reverse-phase high-performance liquid chromatography <xref ref-type="bibr" rid="pone.0035807-Burdick1">[53]</xref>. The molecular mass was identified by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry (UltraFlex II). For the Western blot, transmission electron microscopy (TEM) and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, A&#x3B2; was prepared with hexafluoroisopropanol (HFIP) and dimethyl sulfoxide (DMSO) and incubated at room temperature for the indicated times <xref ref-type="bibr" rid="pone.0035807-Jan1">[54]</xref>. For the thioflavin T (ThT) assay, A&#x3B2; were prepared with guanidine hydrochloride (GdnHCl) and incubated at 25&#xB0;C for the indicated times <xref ref-type="bibr" rid="pone.0035807-Chen1">[27]</xref>, <xref ref-type="bibr" rid="pone.0035807-Jan1">[54]</xref>. For the GdnHCl preps, lyophilized A&#x3B2; was dissolved in 8 M GdnHCl, incubated for 15&#x2013;20 mins, and added to 10 mM Tris-HCl, pH 7.4 (GdnHCl: Tris buffer, 1&#x2236;9 v/v) for refolding. Impurities or aggregates were removed by centrifugation at 17,000&#xD7;g for 20 min at 4&#xB0;C. The supernatant was collected, and the A&#x3B2; concentration was determined by the absorbance at 280 nm (&#x3B5;&#x200A;=&#x200A;1,280 cm<sup>&#x2212;1</sup>M<sup>&#x2212;1</sup>) <xref ref-type="bibr" rid="pone.0035807-Edelhoch1">[55]</xref>. For the HFIP-DMSO preps, lyophilized A&#x3B2; was dissolved in HFIP and incubated for 1 h at room temperature. HFIP was removed by vacuum overnight. HFIP-treated A&#x3B2; films were dissolved in DMSO (A&#x3B2;: DMSO, 1&#x2236;100 w/v) and added to 10 mM Tris-HCl, pH 7.4 (DMSO: Tris, 1&#x2236;9 v/v). After centrifugation at 17,000&#xD7;g at 4&#xB0;C for 20 min, the supernatant was collected and quantified by absorbance at 280 nm.</p>
      </sec>
      <sec id="s4g">
        <title>Photo-induced cross-linking of unmodified proteins (PICUP)</title>
        <p>The experiment was performed as described previously <xref ref-type="bibr" rid="pone.0035807-Bitan1">[25]</xref>, <xref ref-type="bibr" rid="pone.0035807-Chen1">[27]</xref>. Briefly, 9 volumes of A&#x3B2; solution were mixed with 0.5 volume each of 1 mM Tris (2,2&#x2032;-bipyridyl) dichlororuthenium(II) (RuBpy) and 20 mM ammonium persulfate. After mixing, the samples were exposed to a blue light LED in a closed chamber with a manual switch for 10 sec. The cross-linking reaction was stopped by adding SDS-PAGE sample buffer, and the samples were subjected to Tris-Tricine SDS-PAGE.</p>
      </sec>
      <sec id="s4h">
        <title>ThT assay</title>
        <p>25 &#x3BC;M of A&#x3B2; was incubated in 25 &#x3BC;M ThT at 25&#xB0;C in an ELISA plate and monitored with a microplate reader. The ThT emission was measured at 485 nm, while excitation was at 442 nm. The signals were collected automatically every hour for 100 h.</p>
      </sec>
      <sec id="s4i">
        <title>MTT assay</title>
        <p>SH-SY5Y human neuroblastoma cells with &#x223C;75% confluence were treated with A&#x3B2;<sub>wt</sub> or A&#x3B2;<sub>D7H</sub> for 48 hours at 37&#xB0;C. After 48 hours of incubation, the MTT was added, and the cultures were incubated for an additional 3 h. Cells were lysed overnight using a lysis buffer containing 10% SDS and 20 mM HCl. The absorbance was measured at a wavelength of 570 nm by an ELISA reader.</p>
      </sec>
      <sec id="s4j">
        <title>Transmission electron microscopy (TEM)</title>
        <p>10 &#x3BC;l of 25 &#x3BC;M A&#x3B2; samples was placed on glow-discharged, 400-mesh formvar carbon-coated copper grids, negatively stained with 2% uranyl acetate, and examined with a TEM with an accelerating voltage of 75 kV.</p>
      </sec>
      <sec id="s4k">
        <title>Ion titration and Bis-ANS fluorescence</title>
        <p>Fluorescence emission spectra of 4,4-Bis (1-anilinonaphthalene 8-sulfonate) (Bis-ANS) were collected at wavelengths ranging from 450 to 550 nm with an excitation wavelength of 400 nm. 50 &#x3BC;M A&#x3B2; in 5 &#x3BC;M Bis-ANS was titrated with 520 &#x3BC;M ZnCl<sub>2</sub> or CuCl<sub>2</sub> to final ion concentrations in the range of 0&#x2013;20 &#x3BC;M and with 6640 &#x3BC;M ZnCl<sub>2</sub> to final ion concentrations in the range of 20&#x2013;200 &#x3BC;M at 25&#xB0;C in a circulating water bath. The total volume was increased by less than 10% after titration. The signals at 490 nm were used for normalization. The changes of each titration signal to the initial titration signal were normalized to the change of the final titration signal to the initial titration signal. The normalized data were plotted against metal ion concentration.</p>
      </sec>
      <sec id="s4l">
        <title>Metal reduction assay</title>
        <p>A&#x3B2;42<sub>wt</sub> and A&#x3B2;42<sub>D7H</sub> were prepared in the HFIP-DMSO preps. The metal reduction assay was performed as described previously <xref ref-type="bibr" rid="pone.0035807-Huang1">[29]</xref> by using bicinchoninic acid (BCA) assay kit. The working solutions were freshly prepared following the manufacturer's manual. Briefly, the working solution, 200 &#x3BC;l, was added to polystyrene 96-well plate with transparent bottom and 25 &#x3BC;l of A&#x3B2;42<sub>wt</sub> and A&#x3B2;42<sub>D7H</sub> with final concentrations at 10 &#x3BC;M were added into the wells. The plate was then incubated at 37&#xB0;C and read continuously at absorbance of 562 nm by SpectraMax M5 Multi-Mode microplate reader to monitor Cu<sup>+</sup> production. The absorption was generated from the BCA-Cu<sup>+</sup> complex. The saturated absorption at 120 min were obtained, subtracted by the buffer control, averaged (n&#x200A;=&#x200A;3), and normalize to the intensity obtained from A&#x3B2;42<sub>wt</sub>.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material" id="s5">
      <title>Supporting Information</title>
      <supplementary-material content-type="local-data" id="pone.0035807.s001">
        <label>Figure S1</label>
        <caption>
          <p>Pedigree and laboratory data. (A) The pedigree of a Taiwanese family with early onset of AD. The index patient is indicated by an *. The family members with AD are labeled in black. (B) The early-onset AD patient showed normal laboratory data in complete blood count, liver function, thyroid function, renal function and syphilis. This excluded other possibilities from neurodegenerative diseases.</p>
          <p>(TIF)</p>
        </caption>
        <media xlink:href="pone.0035807.s001.tif" mimetype="image" mime-subtype="tiff">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="pone.0035807.s002">
        <label>Figure S2</label>
        <caption>
          <p>Transfect efficiency and APP maturity of wt APP and D7H mutant APP. HEK293 cells were transfected with 0.8 &#x3BC;g pDEST26 plasmid encoding either wt APP or D7H mutant APP. (A) After 24 h, number of cells transfected with APP was analyzed by a mouse anti-APP N-terminus antibody (22C11, red) and number of cell were estimated by DAPI staining (blue). Transfection efficiencies for both plasmids were &#x223C;20%. Scale bar: 50 &#x3BC;m. (B) After 36 h, 30 &#x3BC;g of cell lysates were separated by 8% SDS-PAGEs. APP was analyzed with a mouse anti-APP N-terminus antibody (22C11) and actin was served as loading control. APP expression level was similar in wt APP and D7H mutant APP expressing cells. (C) APPs were separated by 8% SDS-PAGEs and analyzed by anti-APP N-terminus antibody (22C11). Graph showing the fold change of the ratio of mature/immature APP indicates that the ratio of APP maturity of wt APP and D7H mutant APP is similar. Data from wt APP expressing cells were set as 1 in 3 independent experiments and presented as mean &#xB1; SEM.</p>
          <p>(TIF)</p>
        </caption>
        <media xlink:href="pone.0035807.s002.tif" mimetype="image" mime-subtype="tiff">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="pone.0035807.s003">
        <label>Figure S3</label>
        <caption>
          <p>The D7H mutation did not alter intracellular A&#x3B2; level. ELISA showed no significant increase in ratios of A&#x3B2;40/APP, A&#x3B2;42/APP and A&#x3B2;42/40 in the cell lysate of wt APP and D7H mutant APP transfected cells. Data from wt APP expressing cells were set as 1 in 3 independent experiments and presented as mean &#xB1; SEM.</p>
          <p>(TIF)</p>
        </caption>
        <media xlink:href="pone.0035807.s003.tif" mimetype="image" mime-subtype="tiff">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="pone.0035807.s004">
        <label>Figure S4</label>
        <caption>
          <p>Different A&#x3B2; preparations also confirmed that the D7H mutation promotes A&#x3B2;40 HMW assemblies but promotes A&#x3B2;42 LMW assemblies formation. (A, B) Lyophilized A&#x3B2;40 (A) and A&#x3B2;42 (B) were prepared in HFIP-DMSO for the ThT assay. Data were averaged from 3&#x2013;4 independent experiments. (C, D) Lyophilized A&#x3B2;40 (C) and A&#x3B2;42 (D) were prepared in HFIP-DMSO for Western blotting without PICUP treatment.</p>
          <p>(TIF)</p>
        </caption>
        <media xlink:href="pone.0035807.s004.tif" mimetype="image" mime-subtype="tiff">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="pone.0035807.s005">
        <label>Figure S5</label>
        <caption>
          <p>The representative emission spectra of A&#x3B2;40<sub>wt</sub> (A, B) or A&#x3B2;40<sub>D7H</sub> (C, D) in the presence of 0, 10, 20, and 50 &#x3BC;M Zn<sup>2+</sup> (A, C) or Cu<sup>2+</sup> (B, D) are shown.</p>
          <p>(TIF)</p>
        </caption>
        <media xlink:href="pone.0035807.s005.tif" mimetype="image" mime-subtype="tiff">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="pone.0035807.s006">
        <label>Method S1</label>
        <caption>
          <p>Human embryonic kidney (HEK293) cells were from Bioresource Collection and Research Center (60019, Hsinchu, Taiwan). SH-SY5Y human neuroblastoma cells were from Sigma-Aldrich (94030304, MO, USA). MALDI-TOF mass spectrometry was produced by Bruker BioSciences (Bruker Daltonics Ultraflex, MA, USA). The microplate reader for the ThT assay and the BCA assay was produced by Molecule Devices (SpectraMax M5, CA, USA). TEM was produced by Hitachi (H-7000, Tokyo, Japan). Fluorescence microscope was produced by ZEISS (Axio Observer A1, Ireland). Spectrofluorometer for binding affinity was produced by Horiba Jobin Yvon (FluoroMax-3, USA). Copper grids for TEM were purchased from EMS Inc. (18086, PA, USA). Lipofectamin 2000 and pDEST26 were from Invitrogen (11809-019 and 11668-500, USA). The site-directed mutagenesis kit was from Stratagene (200521, CA, USA). Antibody 22C11, AB5352 and 4G8 were from Millipore (MAB348, AB5352 and MAB1561, MA, USA). Antibody for sAPP&#x3B2; was from Convance (9138-005). Antibody for &#x3B2;-actin was from GeneTex (GTX110564, CA, USA). Mounting medium with DAPI was from by Vector Laboratoies (H-1200, CA, USA). ELISA kits for human A&#x3B2;40 and A&#x3B2;42 were purchased from Wako (294-62501 and 290-62601, Japan). GdnHCl was from Merck (1.04220.1000, Darmstadt, Germany). ThT, Trizol, 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP), &#x3B3;-secretase inhibitor (L-685,458), Tris (2,2&#x2032;-bipyridyl) dichlororuthenium (II) (Ru(Bpy)), CuCl<sub>2</sub> and ZnCl<sub>2</sub> were purchased from Sigma-Aldrich (T3516, T9424, 105228, SI-L1790, 224758, 12317 and 31650, MO, USA). Tris and ammonium persulfate (APS) were from Amresco (0826 and 0486, OH, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was from Bio Basic Inc. (298-93-1, Taipei, Taiwan). ELISA reader was produced by SUNRISE, TECAN (Switzerland). The bicinchoninic acid (BCA) assay kit was from Thermo Scientific (Waltham, MA, United States). The polystyrene 96-well plate used for BCA assay was from UltraViolet (Taipei, Taiwan).</p>
          <p>(DOC)</p>
        </caption>
        <media xlink:href="pone.0035807.s006.doc" mimetype="application" mime-subtype="msword">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Tai-Lang Lin at Institute of Cellular and Organismic Biology, and Hui-Ming Yu at Genomics Research Center, Academic Sinica for assisting TEM imaging and A&#x3B2; synthesis.</p>
    </ack>
    <fn-group>
      <fn fn-type="conflict">
        <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p><bold>Funding: </bold>This work was supported by Taiwan National Health Research Institutes NHRI-EX100-9816NC, Taiwan National Science Council grants NSC97-2320-B-010-027-MY3 and NSC100-2320-B-010-020, Taiwan Ministry of Education Aim for Top University Grant (for IHC); Taipei Veterans General Hospital grant V97C1-098 (for CJH); Molecular Medicine Program, Taiwan International Graduate Program, Institute of Biomedical Sciences, Academia Sinica (for WTC); and Genomics Research Center, Academia Sinica, National Science Council grant 98-2320-B-001-020-MY3 (for YRC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="pone.0035807-Hardy1">
        <label>1</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group>
<year>2002</year>
<article-title>The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics.</article-title>
<source>Science</source>
<volume>297</volume>
<fpage>353</fpage>
<lpage>356</lpage>
<pub-id pub-id-type="pmid">12130773</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Lesne1">
        <label>2</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lesne</surname><given-names>S</given-names></name><name><surname>Koh</surname><given-names>MT</given-names></name><name><surname>Kotilinek</surname><given-names>L</given-names></name><name><surname>Kayed</surname><given-names>R</given-names></name><name><surname>Glabe</surname><given-names>CG</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>A specific amyloid-beta protein assembly in the brain impairs memory.</article-title>
<source>Nature</source>
<volume>440</volume>
<fpage>352</fpage>
<lpage>357</lpage>
<pub-id pub-id-type="pmid">16541076</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Shankar1">
        <label>3</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shankar</surname><given-names>GM</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Mehta</surname><given-names>TH</given-names></name><name><surname>Garcia-Munoz</surname><given-names>A</given-names></name><name><surname>Shepardson</surname><given-names>NE</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.</article-title>
<source>Nat Med</source>
<volume>14</volume>
<fpage>837</fpage>
<lpage>842</lpage>
<pub-id pub-id-type="pmid">18568035</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Glabe1">
        <label>4</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glabe</surname><given-names>CG</given-names></name></person-group>
<year>2008</year>
<article-title>Structural Classification of Toxic Amyloid Oligomers.</article-title>
<source>J Biol Chem</source>
<volume>283</volume>
<fpage>29639</fpage>
<lpage>29643</lpage>
<pub-id pub-id-type="pmid">18723507</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Felsenstein1">
        <label>5</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Felsenstein</surname><given-names>KM</given-names></name><name><surname>Hunihan</surname><given-names>LW</given-names></name><name><surname>Roberts</surname><given-names>SB</given-names></name></person-group>
<year>1994</year>
<article-title>Altered cleavage and secretion of a recombinant beta &#x2013; APP bearing the Swedish familial Alzheimer's disease mutation.</article-title>
<source>Nature Genet</source>
<volume>6</volume>
<fpage>251</fpage>
<lpage>256</lpage>
<pub-id pub-id-type="pmid">8012386</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Maruyama1">
        <label>6</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>K</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Shinozaki</surname><given-names>K</given-names></name><name><surname>Kume</surname><given-names>H</given-names></name><name><surname>Asada</surname><given-names>H</given-names></name><etal/></person-group>
<year>1996</year>
<article-title>Familial Alzheimer's disease-linked mutations at Val717 of amyloid precursor protein are specific for the increased secretion of A beta 42(43).</article-title>
<source>Biochem Biophys Res Commun</source>
<volume>227</volume>
<fpage>730</fpage>
<lpage>735</lpage>
<pub-id pub-id-type="pmid">8886002</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Suzuki1">
        <label>7</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>N</given-names></name><name><surname>Cheung</surname><given-names>T</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Odaka</surname><given-names>A</given-names></name><name><surname>Otvos</surname><given-names>L</given-names></name><etal/></person-group>
<year>1994</year>
<article-title>An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.</article-title>
<source>Science</source>
<volume>264</volume>
<fpage>1336</fpage>
<lpage>1340</lpage>
<pub-id pub-id-type="pmid">8191290</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Zhou1">
        <label>8</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Brouwers</surname><given-names>N</given-names></name><name><surname>Benilova</surname><given-names>I</given-names></name><name><surname>Vandersteen</surname><given-names>A</given-names></name><name><surname>Mercken</surname><given-names>M</given-names></name><etal/></person-group>
<year>2011</year>
<article-title>Amyloid precursor protein mutation E682K at the alternative &#x3B2;-secretase cleavage &#x3B2;&#x2032;-site increases A&#x3B2; generation.</article-title>
<source>EMBO Molecular Medicine</source>
<volume>3</volume>
<fpage>291</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="pmid">21500352</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Grabowski1">
        <label>9</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grabowski</surname><given-names>TJ</given-names></name><name><surname>Cho</surname><given-names>HS</given-names></name><name><surname>Vonsattel</surname><given-names>JP</given-names></name><name><surname>Rebeck</surname><given-names>GW</given-names></name><name><surname>Greenberg</surname><given-names>SM</given-names></name></person-group>
<year>2001</year>
<article-title>Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy.</article-title>
<source>Ann Neurol</source>
<volume>49</volume>
<fpage>697</fpage>
<lpage>705</lpage>
<pub-id pub-id-type="pmid">11409420</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Haan1">
        <label>10</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haan</surname><given-names>J</given-names></name><name><surname>Lanser</surname><given-names>JB</given-names></name><name><surname>Zijderveld</surname><given-names>I</given-names></name><name><surname>van der Does</surname><given-names>IG</given-names></name><name><surname>Roos</surname><given-names>RA</given-names></name></person-group>
<year>1990</year>
<article-title>Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type.</article-title>
<source>Arch Neurol</source>
<volume>47</volume>
<fpage>965</fpage>
<lpage>967</lpage>
<pub-id pub-id-type="pmid">2396937</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Hendriks1">
        <label>11</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hendriks</surname><given-names>L</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Cras</surname><given-names>P</given-names></name><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>Van Hul</surname><given-names>W</given-names></name><etal/></person-group>
<year>1992</year>
<article-title>Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the [beta]-amyloid precursor protein gene.</article-title>
<source>Nat Genet</source>
<volume>1</volume>
<fpage>218</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="pmid">1303239</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Nilsberth1">
        <label>12</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nilsberth</surname><given-names>C</given-names></name><name><surname>Westlind-Danielsson</surname><given-names>A</given-names></name><name><surname>Eckman</surname><given-names>CB</given-names></name><name><surname>Condron</surname><given-names>MM</given-names></name><name><surname>Axelman</surname><given-names>K</given-names></name><etal/></person-group>
<year>2001</year>
<article-title>The &#x2018;Arctic&#x2019; APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation.</article-title>
<source>Nat Neurosci</source>
<volume>4</volume>
<fpage>887</fpage>
<lpage>893</lpage>
<pub-id pub-id-type="pmid">11528419</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Cheng1">
        <label>13</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>IH</given-names></name><name><surname>Palop</surname><given-names>JJ</given-names></name><name><surname>Esposito</surname><given-names>LA</given-names></name><name><surname>Bien-Ly</surname><given-names>N</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation.</article-title>
<source>Nat Med</source>
<volume>10</volume>
<fpage>1190</fpage>
<lpage>1192</lpage>
<pub-id pub-id-type="pmid">15502844</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Hori1">
        <label>14</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hori</surname><given-names>Y</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Wakutani</surname><given-names>Y</given-names></name><name><surname>Urakami</surname><given-names>K</given-names></name><name><surname>Nakashima</surname><given-names>K</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate Abeta fibril formation without increasing protofibril formation.</article-title>
<source>J Biol Chem</source>
<volume>282</volume>
<fpage>4916</fpage>
<lpage>4923</lpage>
<pub-id pub-id-type="pmid">17170111</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Golde1">
        <label>15</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Golde</surname><given-names>TE</given-names></name><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>Koo</surname><given-names>EH</given-names></name></person-group>
<year>2011</year>
<article-title>Anti-Amyloid beta Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift.</article-title>
<source>Neuron</source>
<volume>69</volume>
<fpage>203</fpage>
<lpage>213</lpage>
<pub-id pub-id-type="pmid">21262461</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Lovell1">
        <label>16</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lovell</surname><given-names>MA</given-names></name><name><surname>Robertson</surname><given-names>JD</given-names></name><name><surname>Teesdale</surname><given-names>WJ</given-names></name><name><surname>Campbell</surname><given-names>JL</given-names></name><name><surname>Markesbery</surname><given-names>WR</given-names></name></person-group>
<year>1998</year>
<article-title>Copper, iron and zinc in Alzheimer's disease senile plaques.</article-title>
<source>J Neurol Sci</source>
<volume>158</volume>
<fpage>47</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">9667777</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Tugu1">
        <label>17</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>T&#xF5;ugu</surname><given-names>V</given-names></name><name><surname>Tiiman</surname><given-names>A</given-names></name><name><surname>Palumaa</surname><given-names>P</given-names></name></person-group>
<year>2011</year>
<article-title>Interactions of Zn(II) and Cu(II) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity.</article-title>
<source>Metallomics</source>
<volume>3</volume>
<fpage>250</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="pmid">21359283</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Smith1">
        <label>18</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>DG</given-names></name><name><surname>Cappai</surname><given-names>R</given-names></name><name><surname>Barnham</surname><given-names>KJ</given-names></name></person-group>
<year>2007</year>
<article-title>The redox chemistry of the Alzheimer's disease amyloid [beta] peptide.</article-title>
<source>Biochim Biophys Acta</source>
<volume>1768</volume>
<fpage>1976</fpage>
<lpage>1990</lpage>
<pub-id pub-id-type="pmid">17433250</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Minicozzi1">
        <label>19</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Minicozzi</surname><given-names>V</given-names></name><name><surname>Stellato</surname><given-names>F</given-names></name><name><surname>Comai</surname><given-names>M</given-names></name><name><surname>Serra</surname><given-names>MD</given-names></name><name><surname>Potrich</surname><given-names>C</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Identifying the minimal copper- and zinc-binding site sequence in amyloid-beta peptides.</article-title>
<source>J Biol Chem</source>
<volume>283</volume>
<fpage>10784</fpage>
<lpage>10792</lpage>
<pub-id pub-id-type="pmid">18234670</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Nair1">
        <label>20</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nair</surname><given-names>N</given-names></name><name><surname>Perry</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><name><surname>Reddy</surname><given-names>V</given-names></name></person-group>
<year>2010</year>
<article-title>NMR studies of zinc, copper, and iron binding to histidine, the principal metal ion complexing site of amyloid-beta peptide.</article-title>
<source>J Alzheimers Dis</source>
<volume>20</volume>
<fpage>57</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="pmid">20164601</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Duce1">
        <label>21</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duce</surname><given-names>JA</given-names></name><name><surname>Bush</surname><given-names>AI</given-names></name></person-group>
<year>2010</year>
<article-title>Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics.</article-title>
<source>Prog Neurobiol</source>
<volume>92</volume>
<fpage>1</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="pmid">20444428</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Faux1">
        <label>22</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Faux</surname><given-names>N</given-names></name><name><surname>Ritchie</surname><given-names>C</given-names></name><name><surname>Gunn</surname><given-names>A</given-names></name><name><surname>Rembach</surname><given-names>A</given-names></name><name><surname>Tsatsanis</surname><given-names>A</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses J Alzheimers Dis</article-title>
<volume>20</volume>
<fpage>509</fpage>
<lpage>516</lpage>
</element-citation>
      </ref>
      <ref id="pone.0035807-Hegde1">
        <label>23</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hegde</surname><given-names>M</given-names></name><name><surname>Bharathi</surname><given-names>P</given-names></name><name><surname>Suram</surname><given-names>A</given-names></name><name><surname>Venugopal</surname><given-names>C</given-names></name><name><surname>Jagannathan</surname><given-names>R</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Challenges associated with metal chelation therapy in Alzheimer's disease.</article-title>
<source>J Alzheimers Dis</source>
<volume>17</volume>
<fpage>457</fpage>
<lpage>468</lpage>
<pub-id pub-id-type="pmid">19363258</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-OBrien1">
        <label>24</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>RJ</given-names></name><name><surname>Wong</surname><given-names>PC</given-names></name></person-group>
<year>2011</year>
<article-title>Amyloid Precursor Protein Processing and Alzheimer's Disease.</article-title>
<source>Annu Rev Neurosci</source>
<volume>34</volume>
<fpage>185</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="pmid">21456963</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Bitan1">
        <label>25</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bitan</surname><given-names>G</given-names></name><name><surname>Lomakin</surname><given-names>A</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name></person-group>
<year>2001</year>
<article-title>Amyloid beta-Protein Oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins.</article-title>
<source>J Biol Chem</source>
<volume>276</volume>
<fpage>35176</fpage>
<lpage>35184</lpage>
<pub-id pub-id-type="pmid">11441003</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Guerreiro1">
        <label>26</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guerreiro</surname><given-names>RJ</given-names></name><name><surname>Baquero</surname><given-names>M</given-names></name><name><surname>Blesa</surname><given-names>R</given-names></name><name><surname>Boada</surname><given-names>M</given-names></name><name><surname>Bras</surname><given-names>JM</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP.</article-title>
<source>Neurobiol of aging</source>
<volume>31</volume>
<fpage>725</fpage>
<lpage>731</lpage>
</element-citation>
      </ref>
      <ref id="pone.0035807-Chen1">
        <label>27</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>WT</given-names></name><name><surname>Liao</surname><given-names>YH</given-names></name><name><surname>Yu</surname><given-names>HM</given-names></name><name><surname>Cheng</surname><given-names>IH</given-names></name><name><surname>Chen</surname><given-names>YR</given-names></name></person-group>
<year>2011</year>
<article-title>Distinct Effects of Zn2+, Cu2+, Fe3+, and Al3+ on Amyloid-beta Stability, Oligomerization, and Aggregation.</article-title>
<source>J Biol Chem</source>
<volume>286</volume>
<fpage>9646</fpage>
<lpage>9656</lpage>
<pub-id pub-id-type="pmid">21216965</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-LeVine1">
        <label>28</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>LeVine</surname><given-names>H</given-names></name><name><surname>3rd</surname></name></person-group>
<year>2002</year>
<article-title>4,4(&#x2032;)-Dianilino-1,1(&#x2032;)-binaphthyl-5,5(&#x2032;)-disulfonate: report on non-beta-sheet conformers of Alzheimer's peptide beta(1&#x2013;40).</article-title>
<source>Arch Biochem Biophys</source>
<volume>404</volume>
<fpage>106</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="pmid">12127075</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Huang1">
        <label>29</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Cuajungco</surname><given-names>MP</given-names></name><name><surname>Atwood</surname><given-names>CS</given-names></name><name><surname>Hartshorn</surname><given-names>MA</given-names></name><name><surname>Tyndall</surname><given-names>JD</given-names></name><etal/></person-group>
<year>1999</year>
<article-title>Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction.</article-title>
<source>J Bio Chem</source>
<volume>274</volume>
<fpage>37111</fpage>
<lpage>37116</lpage>
<pub-id pub-id-type="pmid">10601271</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Tougu1">
        <label>30</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tougu</surname><given-names>V</given-names></name><name><surname>Karafin</surname><given-names>A</given-names></name><name><surname>Palumaa</surname><given-names>P</given-names></name></person-group>
<year>2008</year>
<article-title>Binding of zinc(II) and copper(II) to the full-length Alzheimer's amyloid-beta peptide.</article-title>
<source>J Neurochem</source>
<volume>104</volume>
<fpage>1249</fpage>
<lpage>1259</lpage>
<pub-id pub-id-type="pmid">18289347</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Tougu2">
        <label>31</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tougu</surname><given-names>V</given-names></name><name><surname>Karafin</surname><given-names>A</given-names></name><name><surname>Zovo</surname><given-names>K</given-names></name><name><surname>Chung</surname><given-names>RS</given-names></name><name><surname>Howells</surname><given-names>C</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Zn(II)- and Cu(II)-induced non-fibrillar aggregates of amyloid-beta(1&#x2013;42) peptide are transformed to amyloid fibrils, both spontaneously and under the influence of metal chelators.</article-title>
<source>J Neurochem</source>
<volume>110</volume>
<fpage>1784</fpage>
<lpage>1795</lpage>
<pub-id pub-id-type="pmid">19619132</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Pedersen1">
        <label>32</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>J</given-names></name><name><surname>&#xD8;stergaard</surname><given-names>J</given-names></name><name><surname>Rozlosnik</surname><given-names>N</given-names></name><name><surname>Gammelgaard</surname><given-names>B</given-names></name><name><surname>Heegaard</surname><given-names>N</given-names></name></person-group>
<year>2011</year>
<article-title>Cu(II) mediates kinetically distinct, non-amyloidogenic aggregation of amyloid-beta peptides.</article-title>
<source>J Biol Chem</source>
<volume>286</volume>
<fpage>26952</fpage>
<lpage>26963</lpage>
<pub-id pub-id-type="pmid">21642429</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-DiFede1">
        <label>33</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Di Fede</surname><given-names>G</given-names></name><name><surname>Catania</surname><given-names>M</given-names></name><name><surname>Morbin</surname><given-names>M</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Suardi</surname><given-names>S</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>A Recessive Mutation in the APP Gene with Dominant-Negative Effect on Amyloidogenesis.</article-title>
<source>Science</source>
<volume>323</volume>
<fpage>1473</fpage>
<lpage>1477</lpage>
<pub-id pub-id-type="pmid">19286555</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-DeJonghe1">
        <label>34</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Jonghe</surname><given-names>C</given-names></name><name><surname>Zehr</surname><given-names>C</given-names></name><name><surname>Yager</surname><given-names>D</given-names></name><name><surname>Prada</surname><given-names>C-M</given-names></name><name><surname>Younkin</surname><given-names>S</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Flemish and Dutch Mutations in Amyloid [beta] Precursor Protein Have Different Effects on Amyloid [beta] Secretion.</article-title>
<source>Neurobiology of Disease</source>
<volume>5</volume>
<fpage>281</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="pmid">9848098</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Phinney1">
        <label>35</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Phinney</surname><given-names>AL</given-names></name><name><surname>Drisaldi</surname><given-names>B</given-names></name><name><surname>Schmidt</surname><given-names>SD</given-names></name><name><surname>Lugowski</surname><given-names>S</given-names></name><name><surname>Coronado</surname><given-names>V</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>In vivo reduction of amyloid-beta by a mutant copper transporter.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>100</volume>
<fpage>14193</fpage>
<lpage>14198</lpage>
<pub-id pub-id-type="pmid">14617772</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Acevedo1">
        <label>36</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Acevedo</surname><given-names>KM</given-names></name><name><surname>Hung</surname><given-names>YH</given-names></name><name><surname>Dalziel</surname><given-names>AH</given-names></name><name><surname>Li</surname><given-names>QX</given-names></name><name><surname>Laughton</surname><given-names>K</given-names></name><etal/></person-group>
<year>2011</year>
<article-title>Copper promotes the trafficking of the amyloid precursor protein.</article-title>
<source>J Biol Chem</source>
<volume>286</volume>
<fpage>8252</fpage>
<lpage>8262</lpage>
<pub-id pub-id-type="pmid">21177866</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Zheng1">
        <label>37</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Xin</surname><given-names>N</given-names></name><name><surname>Chi</surname><given-names>ZH</given-names></name><name><surname>Zhao</surname><given-names>BL</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Divalent metal transporter 1 is involved in amyloid precursor protein processing and Abeta generation.</article-title>
<source>FASEB</source>
<volume>23</volume>
<fpage>4207</fpage>
<lpage>4217</lpage>
</element-citation>
      </ref>
      <ref id="pone.0035807-Wang1">
        <label>38</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>BL</given-names></name><name><surname>Danscher</surname><given-names>G</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Zinc overload enhances APP cleavage and Abeta deposition in the Alzheimer mouse brain.</article-title>
<source>PloS one</source>
<volume>5</volume>
<fpage>e15349</fpage>
<pub-id pub-id-type="pmid">21179415</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Duce2">
        <label>39</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duce</surname><given-names>JA</given-names></name><name><surname>Tsatsanis</surname><given-names>A</given-names></name><name><surname>Cater</surname><given-names>MA</given-names></name><name><surname>James</surname><given-names>SA</given-names></name><name><surname>Robb</surname><given-names>E</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease.</article-title>
<source>Cell</source>
<volume>142</volume>
<fpage>857</fpage>
<lpage>867</lpage>
<pub-id pub-id-type="pmid">20817278</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Dahms1">
        <label>40</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dahms</surname><given-names>SO</given-names></name><name><surname>Konnig</surname><given-names>I</given-names></name><name><surname>Roeser</surname><given-names>D</given-names></name><name><surname>Guhrs</surname><given-names>KH</given-names></name><name><surname>Mayer</surname><given-names>MC</given-names></name><etal/></person-group>
<year>2012</year>
<article-title>Metal Binding Dictates Conformation and Function of the Amyloid Precursor Protein (APP) E2 Domain.</article-title>
<source>J Mol Biol</source>
<volume>416</volume>
<fpage>438</fpage>
<lpage>452</lpage>
<pub-id pub-id-type="pmid">22245578</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Schmidt1">
        <label>41</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Sachse</surname><given-names>C</given-names></name><name><surname>Richter</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Fandrich</surname><given-names>M</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Comparison of Alzheimer Abeta(1&#x2013;40) and Abeta(1&#x2013;42) amyloid fibrils reveals similar protofilament structures.</article-title>
<source>Proc Natl Acad Sci USA</source>
<volume>106</volume>
<fpage>19813</fpage>
<lpage>19818</lpage>
<pub-id pub-id-type="pmid">19843697</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Olofsson1">
        <label>42</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olofsson</surname><given-names>A</given-names></name><name><surname>Lindhagen-Persson</surname><given-names>M</given-names></name><name><surname>Sauer-Eriksson</surname><given-names>AE</given-names></name><name><surname>Ohman</surname><given-names>A</given-names></name></person-group>
<year>2007</year>
<article-title>Amide solvent protection analysis demonstrates that amyloid-beta(1-40) and amyloid-beta(1-42) form different fibrillar structures under identical conditions.</article-title>
<source>Biochem J</source>
<volume>404</volume>
<fpage>63</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">17280549</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Dai1">
        <label>43</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name></person-group>
<year>2010</year>
<article-title>Copper Enhances Amyloid-&#x3B2; Peptide Neurotoxicity and non &#x3B2;-Aggregation: A Series of Experiments Conducted upon Copper-Bound and Copper-Free Amyloid-&#x3B2; Peptide.</article-title>
<source>J Mol Neurosci</source>
<volume>41</volume>
<fpage>66</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="pmid">19685013</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Shin1">
        <label>44</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shin</surname><given-names>BK</given-names></name><name><surname>Saxena</surname><given-names>S</given-names></name></person-group>
<year>2011</year>
<article-title>Substantial contribution of the two imidazole rings of the His13-His14 dyad to Cu(II) binding in amyloid-beta(1&#x2013;16) at physiological pH and its significance.</article-title>
<source>J Physi Chemi A</source>
<volume>115</volume>
<fpage>9590</fpage>
<lpage>9602</lpage>
</element-citation>
      </ref>
      <ref id="pone.0035807-Karr1">
        <label>45</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karr</surname><given-names>JW</given-names></name><name><surname>Akintoye</surname><given-names>H</given-names></name><name><surname>Kaupp</surname><given-names>LJ</given-names></name><name><surname>Szalai</surname><given-names>VA</given-names></name></person-group>
<year>2005</year>
<article-title>N-Terminal deletions modify the Cu2+ binding site in amyloid-beta.</article-title>
<source>Biochemistry</source>
<volume>44</volume>
<fpage>5478</fpage>
<lpage>5487</lpage>
<pub-id pub-id-type="pmid">15807541</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Bush1">
        <label>46</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bush</surname><given-names>AI</given-names></name><name><surname>Pettingell</surname><given-names>WH</given-names></name><name><surname>Multhaup</surname><given-names>G</given-names></name><name><surname>Paradis</surname><given-names>Md</given-names></name><name><surname>Vonsattel</surname><given-names>J-P</given-names></name><etal/></person-group>
<year>1994</year>
<article-title>Rapid Induction of Alzheimer Abeta Amyloid Formation by Zinc.</article-title>
<source>Science</source>
<volume>265</volume>
<fpage>1464</fpage>
<lpage>1467</lpage>
<pub-id pub-id-type="pmid">8073293</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Miller1">
        <label>47</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Nussinov</surname><given-names>R</given-names></name></person-group>
<year>2010</year>
<article-title>Zinc ions promote Alzheimer Abeta aggregation via population shift of polymorphic states.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>107</volume>
<fpage>9490</fpage>
<lpage>9495</lpage>
<pub-id pub-id-type="pmid">20448202</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Clements1">
        <label>48</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clements</surname><given-names>A</given-names></name><name><surname>Allsop</surname><given-names>D</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name></person-group>
<year>1996</year>
<article-title>Aggregation and Metal-Binding Properties of Mutant Forms of the Amyloid Beta Peptide of Alzheimer's Disease.</article-title>
<source>J Neurochem</source>
<volume>66</volume>
<fpage>740</fpage>
<lpage>747</lpage>
<pub-id pub-id-type="pmid">8592147</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Nakamura1">
        <label>49</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Shishido</surname><given-names>N</given-names></name><name><surname>Nunomura</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>MA</given-names></name><name><surname>Perry</surname><given-names>G</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron.</article-title>
<source>Biochemistry</source>
<volume>46</volume>
<fpage>12737</fpage>
<lpage>12743</lpage>
<pub-id pub-id-type="pmid">17929832</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Barnham1">
        <label>50</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barnham</surname><given-names>KJ</given-names></name><name><surname>Haeffner</surname><given-names>F</given-names></name><name><surname>Ciccotosto</surname><given-names>GD</given-names></name><name><surname>Curtain</surname><given-names>CC</given-names></name><name><surname>Tew</surname><given-names>D</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid.</article-title>
<source>FASEB J</source>
<volume>18</volume>
<fpage>1427</fpage>
<lpage>1429</lpage>
<pub-id pub-id-type="pmid">15231727</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Smith2">
        <label>51</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>DP</given-names></name><name><surname>Ciccotosto</surname><given-names>GD</given-names></name><name><surname>Tew</surname><given-names>DJ</given-names></name><name><surname>Fodero-Tavoletti</surname><given-names>MT</given-names></name><name><surname>Johanssen</surname><given-names>T</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Concentration Dependent Cu2+ Induced Aggregation and Dityrosine Formation of the Alzheimer's Disease Amyloid-beta Peptide.</article-title>
<source>Biochemistry</source>
<volume>46</volume>
<fpage>2881</fpage>
<lpage>2891</lpage>
<pub-id pub-id-type="pmid">17297919</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Atwood1">
        <label>52</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Atwood</surname><given-names>CS</given-names></name><name><surname>Perry</surname><given-names>G</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Jones</surname><given-names>WD</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta.</article-title>
<source>Biochemistry</source>
<volume>43</volume>
<fpage>560</fpage>
<lpage>568</lpage>
<pub-id pub-id-type="pmid">14717612</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Burdick1">
        <label>53</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burdick</surname><given-names>D</given-names></name><name><surname>Soreghan</surname><given-names>B</given-names></name><name><surname>Kwon</surname><given-names>M</given-names></name><name><surname>Kosmoski</surname><given-names>J</given-names></name><name><surname>Knauer</surname><given-names>M</given-names></name><etal/></person-group>
<year>1992</year>
<article-title>Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs.</article-title>
<source>J Biol Chem</source>
<volume>267</volume>
<fpage>546</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="pmid">1730616</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Jan1">
        <label>54</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jan</surname><given-names>A</given-names></name><name><surname>Hartley</surname><given-names>D</given-names></name><name><surname>Lashuel</surname><given-names>H</given-names></name></person-group>
<year>1992</year>
<article-title>Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research.</article-title>
<source>Nat Protoc</source>
<volume>5</volume>
<fpage>1186</fpage>
<lpage>1209</lpage>
<pub-id pub-id-type="pmid">20539293</pub-id></element-citation>
      </ref>
      <ref id="pone.0035807-Edelhoch1">
        <label>55</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Edelhoch</surname><given-names>H</given-names></name></person-group>
<year>1967</year>
<article-title>Spectroscopic determination of tryptophan and tyrosine in proteins.</article-title>
<source>Biochemistry</source>
<volume>6</volume>
<fpage>1948</fpage>
<lpage>1954</lpage>
<pub-id pub-id-type="pmid">6049437</pub-id></element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
